SlideShare a Scribd company logo
HDACs
(Histone Deacetylases)
KRVS Chaitanya
• Histone deacetylases (HDAC) are a class
of enzymes that remove acetyl groups (O=C-CH3)
from an ε-N-acetyl lysine amino acid on a histone,
allowing the histone to wrap the DNA more tightly.
• This is important because DNA is wrapped around
histone, and DNA expression is regulated by
acetylation and de-acetylation.
• Its action is opposite to that of histone
acetyltransferase.
• HDAC proteins are now also called lysine
deacetylases (KDAC), to describe their function
rather than their target, which also includes non-
histone proteins
HDAC super family
• Together with the acetyl polyamine
amidohydrolases and the acetoin utilization proteins,
the histone deacetylases form an ancient protein
superfamily known as the histone deacetylases
superfamily.
• Classes of HDACs in higher eukaryotes.
• HDACs, are classified in four classes depending on
sequence homology to the yeast original enzymes and
domain organization:
Classification of HDACs
• HDAC (except class III) contain zinc and are known as
Zn2+-Dependent Histone Deacetylases.
• They feature a classical arginase fold and are structurally
and mechanistically distinct from sirtuins (class III),
which fold into a Rossmann architecture and
are NAD+ dependent.
Subtypes
• HDAC proteins are grouped into four classes based on function and DNA
sequence similarity.
• Class I, II and IV are considered "classical" HDACs whose activities are
inhibited by trichostatin A (TSA) and have a zinc dependent active site,
whereas Class III enzymes are a family of NAD+-dependent proteins known
as sirtuins and are not affected by TSA.
• Homologues to these three groups are found in yeast having the names:
reduced potassium dependency 3 (Rpd3), which corresponds to Class I; histone
deacetylases 1 (hda1), corresponding to Class II; and silent information
regulator 2 (Sir2), corresponding to Class III.
• Class IV contains just one isoform (HDAC11), which is not
highly homologous with either Rpd3 or hda1 yeast
enzymes, and therefore HDAC11 is assigned to its own class.
• The Class III enzymes are considered a separate type of
enzyme and have a different mechanism of action; these
enzymes are NAD+-dependent, whereas HDACs in other
classes require Zn2+ as a cofactor.
Evolution
• HDACs are conserved across evolution, showing orthologs in
all eukaryotes and even in Archaea.
• All upper eukaryotes, including vertebrates, plants and
arthropods, possess at least one HDAC per class, while most
vertebrates carry the 11 canonical HDACs, with the exception
of bone fish, which lack HDAC2 but appears to have an extra
copy of HDAC11, dubbed HDAC12.
• Plants carry additional HDACs compared to animals,
putatively to carry out the more complex transcriptional
regulation required by these sessile organisms.
• HDACs appear to be deriving from an ancestral acetyl-binding
domain, as HDAC homologs have been found in bacteria in
the form of Acetoin utilization proteins (AcuC) proteins
Sub cellular distribution
• Within the Class I HDACs, HDAC 1, 2, and 3 are found
primarily in the nucleus, whereas HDAC8 is found in both the
nucleus and the cytoplasm, and is also membrane-associated.
• Class II HDACs (HDAC4, 5, 6, 7 9, and 10) are able to shuttle
in and out of the nucleus, depending on different signals.
• HDAC6 is a cytoplasmic, microtubule-associated
enzyme.
• HDAC6 deacetylates tubulin, Hsp90, and cortactin,
and forms complexes with other partner proteins, and
is, therefore, involved in a variety of biological
processes.
Function
Histone modification:
• Histone tails are normally positively charged due to amine groups
present on their lysine and arginine amino acids.
• These positive charges help the histone tails to interact with and
bind to the negatively charged phosphate groups on the DNA
backbone.
• Acetylation, which occurs normally in a cell, neutralizes the positive
charges on the histone by changing amines into amides and
decreases the ability of the histone to bind to DNA.
• This decreased binding allows chromatin expansion,
permitting genetic transcription to take place.
• Histone deacetylases remove those acetyl groups, increasing
the positive charge of histone tails and encouraging high-
affinity binding between the histones and DNA backbone.
• The increased DNA binding condenses DNA structure,
preventing transcription.
• Histone deacetylases is involved in a series of pathways
within the living system.
• According to the Kyoto Encyclopaedia of Genes and
Genomes (KEGG), these are:
1. Environmental information processing; signal
transduction; notch signalling pathway
2. Cellular processes; cell growth and death; cell cycle
3. Human diseases; cancers; chronic myeloid leukaemia
• Histone acetylation plays an important role in the regulation of
gene expression.
• Hyper acetylated chromatin is transcriptionally active, and
hypoacetylated chromatin is silent.
• A study on mice found that a specific subset of mouse genes
(7%) was deregulated in the absence of HDAC1.
• Their study also found a regulatory crosstalk
between HDAC1 and HDAC2 and suggest a novel function
for HDAC1 as a transcriptional coactivator.
• HDAC1 expression was found to be increased in the prefrontal
cortex of schizophrenia subjects negatively correlating with
the expression of GAD67 mRNA.
Non-histone effects
• It is a mistake to regard HDACs solely in the context of regulating
gene transcription by modifying histones and chromatin structure,
although that appears to be the predominant function. The function,
activity, and stability of proteins can be controlled by post-
translational modifications.
• Protein phosphorylation is perhaps the most widely studied and
understood modification in which certain amino acid residues are
phosphorylated by the action of protein kinases or dephosphorylated
by the action of phosphatases.
• The acetylation of lysine residues is emerging as an
analogous mechanism, in which non-histone proteins are
acted on by acetylases and deacetylases.
• It is in this context that HDACs are being found to
interact with a variety of non-histone proteins—some of
these are transcription factors and co-regulators, some are
not.
Note the following four examples:
1. HDAC6 is associated with aggresomes.
– Misfolded protein aggregates are tagged by ubiquitination and removed
from the cytoplasm by dynein motors via the microtubule network to an
organelle termed the aggresome.
– HDAC 6 binds polyubiquitinated misfolded proteins and links to dynein
motors, thereby allowing the misfolded protein cargo to be physically
transported to chaperones and proteasomes for subsequent destruction.
– HDAC6 is important regulator of HSP90 function and its inhibitor
proposed to treat metabolic disorders.
2. PTEN is an important phosphatase involved in cell signaling
via phosphoinositols and the AKT/PI3 kinase pathway.
• PTEN is subject to complex regulatory control via
phosphorylation, ubiquitination, oxidation and acetylation.
• Acetylation of PTEN by the histone acetyltransferase
p300/CBP-associated factor (PCAF) can repress its activity;
on the converse, deacetylation of PTEN by SIRT1 deacetylase
and, by HDAC1, can stimulate its activity.
3. APE1/Ref-1 (APEX1) is a multifunctional protein possessing both
DNA repair activity (on abasic and single-strand break sites) and
transcriptional regulatory activity associated with oxidative stress.
• APE1/Ref-1 is acetylated by PCAF; on the converse, it is stably
associated with and deacetylated by Class I HDACs.
• The acetylation state of APE1/Ref-1 does not appear to affect
its DNA repair activity, but it does regulate its transcriptional
activity such as its ability to bind to the PTH promoter and initiate
transcription of the parathyroid hormone gene.
4. NF-κB is a key transcription factor and effector molecule
involved in responses to cell stress, consisting of a p50/p65
heterodimer.
• The p65 subunit is controlled by acetylation via PCAF and by
deacetylation via HDAC3 and HDAC6.
Neurodegenerative diseases
• Inherited mutations in the gene encoding FUS,
an RNA/DNA binding protein, are causally linked
to amyotrophic lateral sclerosis (ALS).
• FUS has a pivotal role in the DNA damage response involving
its direct interaction with histone deacetylase 1 (HDAC1).
• ALS mutant FUS proteins are defective in the DNA damage
response and in recombinational DNA repair, and also show
reduced interaction with HDAC1.
• Ataxia-telangiectasia is due to mutation in the Atm gene. Wild-
type Atm encodes a protein kinase employed in chromatin
remodeling and in epigenetic alterations that are required
for repairing DNA double-strand breaks.
• Atm mutation causes neurons to accumulate nuclear histone
deacetylase 4 (HDAC4) resulting in increased histone deacetylation
and altered neuronal gene expression that likely contributes to
the neurodegeneration characteristic of ataxia-telangiectasia.
HDAC inhibitors
• Histone deacetylase inhibitors (HDIs) have a long history of use in
psychiatry and neurology as mood stabilizers and anti-epileptics, for
example, valproic acid.
• In more recent times, HDIs are being studied as a mitigator or treatment
for neurodegenerative diseases.
• Also in recent years, there has been an effort to develop HDIs for cancer
therapy.
• Vorinostat (SAHA) was FDA approved in 2006 for the treatment of
cutaneous manifestations in patients with cutaneous T cell
lymphoma (CTCL) that have failed previous treatments.
• A second HDI, Istodax (romidepsin), was approved in 2009 for
patients with CTCL. The exact mechanisms by which the
compounds may work are unclear, but epigenetic pathways are
proposed.
• In addition, a clinical trial is studying valproic acid effects on the
latent pools of HIV in infected persons.
• HDIs are currently being investigated as chemosensitizers for
cytotoxic chemotherapy or radiation therapy, or in association with
DNA methylation inhibitors based on in vitro synergy.
• Isoform selective HDIs which can aid in elucidating role of
individual HDAC isoforms have been developed.
• HDAC inhibitors have effects on non-histone proteins that
are related to acetylation.
• HDIs can alter the degree of acetylation of these molecules
and, therefore, increase or repress their activity.
• For the four examples given above (see Function) on
HDACs acting on non-histone proteins, in each of those
instances the HDAC inhibitor Trichostatin A (TSA) blocks
the effect.
• HDIs have been shown to alter the activity of many
transcription factors, including ACTR, cMyb,
E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70,
NFκB, PCNA, p53, RB, Runx, SF1 Sp3, STAT, TFIIE, TCF,
YY1.
• The ketone body β-hydroxybutyrate has been shown in mice to
increase gene expression of FOXO3a by histone deacetylases inhibition.
• Histone deacetylases inhibitors may modulate the latency of some viruses,
resulting in reactivation.
• This has been shown to occur, for instance, with a latent human
herpesvirus-6 infection.
• Histone deacetylases inhibitors have shown activity against
certain Plasmodium species and stages which may indicate they have
potential in malaria treatment. It has been shown that HDIs accumulate
acetylated histone H3K9/H3K14, a downstream target of class I HDACs.
Thank you

More Related Content

What's hot

MAPK pathway,
MAPK pathway, MAPK pathway,
MAPK pathway,
Dr. Sandeep Kumar Singh
 
Jak stat signalling pathway
Jak stat signalling pathwayJak stat signalling pathway
Jak stat signalling pathway
Amit Sahoo
 
Jak stat
Jak statJak stat
Jak stat
Pram Priyanca
 
Cell signalling
Cell signalling Cell signalling
Cell signalling
Sindhoora Shetty
 
Nuclear Receptors
Nuclear ReceptorsNuclear Receptors
Tyrosine kinase ppt
Tyrosine kinase pptTyrosine kinase ppt
Tyrosine kinase ppt
Charan Ingole
 
TRANSCRIPTION AND TRANSCRIPTION FACTORS
TRANSCRIPTION AND TRANSCRIPTION FACTORSTRANSCRIPTION AND TRANSCRIPTION FACTORS
TRANSCRIPTION AND TRANSCRIPTION FACTORS
Koppala RVS Chaitanya
 
SiRNA
SiRNA SiRNA
Receptor tyrosine kinase
Receptor tyrosine kinaseReceptor tyrosine kinase
Receptor tyrosine kinase
Sobia
 
antisense technology
antisense technologyantisense technology
antisense technology
DESH BANDHU GANGWAR
 
Cell cycle and regulation
Cell cycle and regulationCell cycle and regulation
Cell cycle and regulation
Tushar Morankar
 
MAPK -Ras pathway
MAPK -Ras pathwayMAPK -Ras pathway
MAPK -Ras pathway
Koppala RVS Chaitanya
 
Map kinase and jak stat pathway
Map kinase and jak stat pathway Map kinase and jak stat pathway
Map kinase and jak stat pathway
DHINESHKUMAR V
 
Gene mapping and sequencing
Gene mapping and sequencingGene mapping and sequencing
Gene mapping and sequencing
PREETAM PALKAR
 
RECOMBINANT DNA TECHNOLOGY
RECOMBINANT DNA TECHNOLOGYRECOMBINANT DNA TECHNOLOGY
RECOMBINANT DNA TECHNOLOGY
YESANNA
 
Receptor tyrosine kinases.ppt
Receptor tyrosine kinases.pptReceptor tyrosine kinases.ppt
Receptor tyrosine kinases.ppt
Dr. Khuram Aziz
 
Epigenetics- Transcription regulation of gene expression
Epigenetics- Transcription regulation of gene expressionEpigenetics- Transcription regulation of gene expression
Epigenetics- Transcription regulation of gene expression
akash mahadev
 
Secondary messengers system
Secondary messengers systemSecondary messengers system
Secondary messengers system
FoziyaKhan
 
Protein kinases
Protein kinasesProtein kinases
Protein kinases
MukulTambe
 
mi RNA and siRNA
mi RNA and siRNAmi RNA and siRNA
mi RNA and siRNA
microbiology Notes
 

What's hot (20)

MAPK pathway,
MAPK pathway, MAPK pathway,
MAPK pathway,
 
Jak stat signalling pathway
Jak stat signalling pathwayJak stat signalling pathway
Jak stat signalling pathway
 
Jak stat
Jak statJak stat
Jak stat
 
Cell signalling
Cell signalling Cell signalling
Cell signalling
 
Nuclear Receptors
Nuclear ReceptorsNuclear Receptors
Nuclear Receptors
 
Tyrosine kinase ppt
Tyrosine kinase pptTyrosine kinase ppt
Tyrosine kinase ppt
 
TRANSCRIPTION AND TRANSCRIPTION FACTORS
TRANSCRIPTION AND TRANSCRIPTION FACTORSTRANSCRIPTION AND TRANSCRIPTION FACTORS
TRANSCRIPTION AND TRANSCRIPTION FACTORS
 
SiRNA
SiRNA SiRNA
SiRNA
 
Receptor tyrosine kinase
Receptor tyrosine kinaseReceptor tyrosine kinase
Receptor tyrosine kinase
 
antisense technology
antisense technologyantisense technology
antisense technology
 
Cell cycle and regulation
Cell cycle and regulationCell cycle and regulation
Cell cycle and regulation
 
MAPK -Ras pathway
MAPK -Ras pathwayMAPK -Ras pathway
MAPK -Ras pathway
 
Map kinase and jak stat pathway
Map kinase and jak stat pathway Map kinase and jak stat pathway
Map kinase and jak stat pathway
 
Gene mapping and sequencing
Gene mapping and sequencingGene mapping and sequencing
Gene mapping and sequencing
 
RECOMBINANT DNA TECHNOLOGY
RECOMBINANT DNA TECHNOLOGYRECOMBINANT DNA TECHNOLOGY
RECOMBINANT DNA TECHNOLOGY
 
Receptor tyrosine kinases.ppt
Receptor tyrosine kinases.pptReceptor tyrosine kinases.ppt
Receptor tyrosine kinases.ppt
 
Epigenetics- Transcription regulation of gene expression
Epigenetics- Transcription regulation of gene expressionEpigenetics- Transcription regulation of gene expression
Epigenetics- Transcription regulation of gene expression
 
Secondary messengers system
Secondary messengers systemSecondary messengers system
Secondary messengers system
 
Protein kinases
Protein kinasesProtein kinases
Protein kinases
 
mi RNA and siRNA
mi RNA and siRNAmi RNA and siRNA
mi RNA and siRNA
 

Similar to HDACs (Histone Deacetylases)

Epigenetics
Epigenetics  Epigenetics
HEXOSE MONOPHOSPHATE SHUNT
HEXOSE MONOPHOSPHATE SHUNTHEXOSE MONOPHOSPHATE SHUNT
Chaperones
Chaperones Chaperones
Chaperones
Hadeeqa Aiman
 
pentosephosphate.ppt
pentosephosphate.pptpentosephosphate.ppt
pentosephosphate.ppt
El Saadany Mohamad
 
HDAC11, A New Target For Cancer.pptx
HDAC11, A New Target For Cancer.pptxHDAC11, A New Target For Cancer.pptx
HDAC11, A New Target For Cancer.pptx
Swapnamay Halder
 
Eukaryotic gene Regulation II 2014
Eukaryotic gene Regulation II 2014  Eukaryotic gene Regulation II 2014
Eukaryotic gene Regulation II 2014
Jill Howlin
 
Chromatin remodeling
Chromatin remodelingChromatin remodeling
Gene expression in eukaryotes 1
Gene expression in eukaryotes 1Gene expression in eukaryotes 1
Gene expression in eukaryotes 1
YPSPrime
 
Regulation of Gene Expression-SH.pdf
Regulation of Gene Expression-SH.pdfRegulation of Gene Expression-SH.pdf
Regulation of Gene Expression-SH.pdf
MSCW Mysore
 
Adapalene, Etanercept and Triptane. mirfa
Adapalene, Etanercept and Triptane. mirfaAdapalene, Etanercept and Triptane. mirfa
Adapalene, Etanercept and Triptane. mirfa
Mirfaidah Nadjamuddin
 
HDAC3 indirectly modulates tubulin acetylation
HDAC3 indirectly modulates tubulin acetylation HDAC3 indirectly modulates tubulin acetylation
HDAC3 indirectly modulates tubulin acetylation
Caroline Seiler
 
PPARs
PPARsPPARs
Histones
HistonesHistones
Histones
AnuKiruthika
 
Final nuclear receptor
Final nuclear receptorFinal nuclear receptor
Final nuclear receptor
DR.HARI SINGH GOUR
 
Sindrome di rett
Sindrome di rettSindrome di rett
Sindrome di rett
iva martini
 
Dna modifications
Dna modificationsDna modifications
Dna modifications
Hafiz M Waseem
 
Eicosanoids
EicosanoidsEicosanoids
Eicosanoids
Darpan Phagiwala
 
Epigenetic modulators - review - BMCL digest
Epigenetic modulators - review - BMCL digestEpigenetic modulators - review - BMCL digest
Epigenetic modulators - review - BMCL digest
Boobalan Pachaiyappan
 
Anti histamines drugs
Anti histamines drugsAnti histamines drugs
Anti histamines drugs
Ravish Yadav
 
Molbiol 2011-12-eukaryotic gene-expression
Molbiol 2011-12-eukaryotic gene-expressionMolbiol 2011-12-eukaryotic gene-expression
Molbiol 2011-12-eukaryotic gene-expression
Nikolay Vyahhi
 

Similar to HDACs (Histone Deacetylases) (20)

Epigenetics
Epigenetics  Epigenetics
Epigenetics
 
HEXOSE MONOPHOSPHATE SHUNT
HEXOSE MONOPHOSPHATE SHUNTHEXOSE MONOPHOSPHATE SHUNT
HEXOSE MONOPHOSPHATE SHUNT
 
Chaperones
Chaperones Chaperones
Chaperones
 
pentosephosphate.ppt
pentosephosphate.pptpentosephosphate.ppt
pentosephosphate.ppt
 
HDAC11, A New Target For Cancer.pptx
HDAC11, A New Target For Cancer.pptxHDAC11, A New Target For Cancer.pptx
HDAC11, A New Target For Cancer.pptx
 
Eukaryotic gene Regulation II 2014
Eukaryotic gene Regulation II 2014  Eukaryotic gene Regulation II 2014
Eukaryotic gene Regulation II 2014
 
Chromatin remodeling
Chromatin remodelingChromatin remodeling
Chromatin remodeling
 
Gene expression in eukaryotes 1
Gene expression in eukaryotes 1Gene expression in eukaryotes 1
Gene expression in eukaryotes 1
 
Regulation of Gene Expression-SH.pdf
Regulation of Gene Expression-SH.pdfRegulation of Gene Expression-SH.pdf
Regulation of Gene Expression-SH.pdf
 
Adapalene, Etanercept and Triptane. mirfa
Adapalene, Etanercept and Triptane. mirfaAdapalene, Etanercept and Triptane. mirfa
Adapalene, Etanercept and Triptane. mirfa
 
HDAC3 indirectly modulates tubulin acetylation
HDAC3 indirectly modulates tubulin acetylation HDAC3 indirectly modulates tubulin acetylation
HDAC3 indirectly modulates tubulin acetylation
 
PPARs
PPARsPPARs
PPARs
 
Histones
HistonesHistones
Histones
 
Final nuclear receptor
Final nuclear receptorFinal nuclear receptor
Final nuclear receptor
 
Sindrome di rett
Sindrome di rettSindrome di rett
Sindrome di rett
 
Dna modifications
Dna modificationsDna modifications
Dna modifications
 
Eicosanoids
EicosanoidsEicosanoids
Eicosanoids
 
Epigenetic modulators - review - BMCL digest
Epigenetic modulators - review - BMCL digestEpigenetic modulators - review - BMCL digest
Epigenetic modulators - review - BMCL digest
 
Anti histamines drugs
Anti histamines drugsAnti histamines drugs
Anti histamines drugs
 
Molbiol 2011-12-eukaryotic gene-expression
Molbiol 2011-12-eukaryotic gene-expressionMolbiol 2011-12-eukaryotic gene-expression
Molbiol 2011-12-eukaryotic gene-expression
 

More from Koppala RVS Chaitanya

Respirtory stimulants.pdf
Respirtory stimulants.pdfRespirtory stimulants.pdf
Respirtory stimulants.pdf
Koppala RVS Chaitanya
 
Nasal Decongestants.pdf
Nasal Decongestants.pdfNasal Decongestants.pdf
Nasal Decongestants.pdf
Koppala RVS Chaitanya
 
Expectorants and Antitussives.pdf
Expectorants and Antitussives.pdfExpectorants and Antitussives.pdf
Expectorants and Antitussives.pdf
Koppala RVS Chaitanya
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdf
Koppala RVS Chaitanya
 
Digestants and Carminatives.pdf
Digestants and Carminatives.pdfDigestants and Carminatives.pdf
Digestants and Carminatives.pdf
Koppala RVS Chaitanya
 
THYROID HORMONES AND THYROID INHIBITORS.pdf
THYROID HORMONES AND THYROID INHIBITORS.pdfTHYROID HORMONES AND THYROID INHIBITORS.pdf
THYROID HORMONES AND THYROID INHIBITORS.pdf
Koppala RVS Chaitanya
 
CORTICOSTERIODS.pdf
CORTICOSTERIODS.pdfCORTICOSTERIODS.pdf
CORTICOSTERIODS.pdf
Koppala RVS Chaitanya
 
Anterior Pituitary Hormones.pdf
Anterior Pituitary Hormones.pdfAnterior Pituitary Hormones.pdf
Anterior Pituitary Hormones.pdf
Koppala RVS Chaitanya
 
Anti gout drugs.pdf
Anti gout drugs.pdfAnti gout drugs.pdf
Anti gout drugs.pdf
Koppala RVS Chaitanya
 
Anti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdfAnti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdf
Koppala RVS Chaitanya
 
Non Steroidal Anti inflammatory Drugs.pdf
Non Steroidal Anti inflammatory Drugs.pdfNon Steroidal Anti inflammatory Drugs.pdf
Non Steroidal Anti inflammatory Drugs.pdf
Koppala RVS Chaitanya
 
Histamine.pptx
Histamine.pptxHistamine.pptx
Histamine.pptx
Koppala RVS Chaitanya
 
PHARMACOLOGY EXPERIMENTS.pdf
PHARMACOLOGY EXPERIMENTS.pdfPHARMACOLOGY EXPERIMENTS.pdf
PHARMACOLOGY EXPERIMENTS.pdf
Koppala RVS Chaitanya
 
Antiplatelet drugs pharmacology.pdf
Antiplatelet drugs pharmacology.pdfAntiplatelet drugs pharmacology.pdf
Antiplatelet drugs pharmacology.pdf
Koppala RVS Chaitanya
 
Shock.pdf
Shock.pdfShock.pdf
Morphine Poisoning.pdf
Morphine Poisoning.pdfMorphine Poisoning.pdf
Morphine Poisoning.pdf
Koppala RVS Chaitanya
 
Barbiturate Poisoning.pdf
Barbiturate Poisoning.pdfBarbiturate Poisoning.pdf
Barbiturate Poisoning.pdf
Koppala RVS Chaitanya
 
CHRONOTHERAPY.pdf
CHRONOTHERAPY.pdfCHRONOTHERAPY.pdf
CHRONOTHERAPY.pdf
Koppala RVS Chaitanya
 
MONOCLONAL ANITBODIES.pdf
MONOCLONAL ANITBODIES.pdfMONOCLONAL ANITBODIES.pdf
MONOCLONAL ANITBODIES.pdf
Koppala RVS Chaitanya
 
Heavy Metal Poisoning.pdf
Heavy Metal Poisoning.pdfHeavy Metal Poisoning.pdf
Heavy Metal Poisoning.pdf
Koppala RVS Chaitanya
 

More from Koppala RVS Chaitanya (20)

Respirtory stimulants.pdf
Respirtory stimulants.pdfRespirtory stimulants.pdf
Respirtory stimulants.pdf
 
Nasal Decongestants.pdf
Nasal Decongestants.pdfNasal Decongestants.pdf
Nasal Decongestants.pdf
 
Expectorants and Antitussives.pdf
Expectorants and Antitussives.pdfExpectorants and Antitussives.pdf
Expectorants and Antitussives.pdf
 
Appeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdfAppeptite stimulants and suppresents.pdf
Appeptite stimulants and suppresents.pdf
 
Digestants and Carminatives.pdf
Digestants and Carminatives.pdfDigestants and Carminatives.pdf
Digestants and Carminatives.pdf
 
THYROID HORMONES AND THYROID INHIBITORS.pdf
THYROID HORMONES AND THYROID INHIBITORS.pdfTHYROID HORMONES AND THYROID INHIBITORS.pdf
THYROID HORMONES AND THYROID INHIBITORS.pdf
 
CORTICOSTERIODS.pdf
CORTICOSTERIODS.pdfCORTICOSTERIODS.pdf
CORTICOSTERIODS.pdf
 
Anterior Pituitary Hormones.pdf
Anterior Pituitary Hormones.pdfAnterior Pituitary Hormones.pdf
Anterior Pituitary Hormones.pdf
 
Anti gout drugs.pdf
Anti gout drugs.pdfAnti gout drugs.pdf
Anti gout drugs.pdf
 
Anti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdfAnti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdf
 
Non Steroidal Anti inflammatory Drugs.pdf
Non Steroidal Anti inflammatory Drugs.pdfNon Steroidal Anti inflammatory Drugs.pdf
Non Steroidal Anti inflammatory Drugs.pdf
 
Histamine.pptx
Histamine.pptxHistamine.pptx
Histamine.pptx
 
PHARMACOLOGY EXPERIMENTS.pdf
PHARMACOLOGY EXPERIMENTS.pdfPHARMACOLOGY EXPERIMENTS.pdf
PHARMACOLOGY EXPERIMENTS.pdf
 
Antiplatelet drugs pharmacology.pdf
Antiplatelet drugs pharmacology.pdfAntiplatelet drugs pharmacology.pdf
Antiplatelet drugs pharmacology.pdf
 
Shock.pdf
Shock.pdfShock.pdf
Shock.pdf
 
Morphine Poisoning.pdf
Morphine Poisoning.pdfMorphine Poisoning.pdf
Morphine Poisoning.pdf
 
Barbiturate Poisoning.pdf
Barbiturate Poisoning.pdfBarbiturate Poisoning.pdf
Barbiturate Poisoning.pdf
 
CHRONOTHERAPY.pdf
CHRONOTHERAPY.pdfCHRONOTHERAPY.pdf
CHRONOTHERAPY.pdf
 
MONOCLONAL ANITBODIES.pdf
MONOCLONAL ANITBODIES.pdfMONOCLONAL ANITBODIES.pdf
MONOCLONAL ANITBODIES.pdf
 
Heavy Metal Poisoning.pdf
Heavy Metal Poisoning.pdfHeavy Metal Poisoning.pdf
Heavy Metal Poisoning.pdf
 

Recently uploaded

Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 

Recently uploaded (20)

Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 

HDACs (Histone Deacetylases)

  • 2. • Histone deacetylases (HDAC) are a class of enzymes that remove acetyl groups (O=C-CH3) from an ε-N-acetyl lysine amino acid on a histone, allowing the histone to wrap the DNA more tightly. • This is important because DNA is wrapped around histone, and DNA expression is regulated by acetylation and de-acetylation.
  • 3. • Its action is opposite to that of histone acetyltransferase. • HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non- histone proteins
  • 4.
  • 5. HDAC super family • Together with the acetyl polyamine amidohydrolases and the acetoin utilization proteins, the histone deacetylases form an ancient protein superfamily known as the histone deacetylases superfamily.
  • 6. • Classes of HDACs in higher eukaryotes. • HDACs, are classified in four classes depending on sequence homology to the yeast original enzymes and domain organization:
  • 7.
  • 9.
  • 10.
  • 11. • HDAC (except class III) contain zinc and are known as Zn2+-Dependent Histone Deacetylases. • They feature a classical arginase fold and are structurally and mechanistically distinct from sirtuins (class III), which fold into a Rossmann architecture and are NAD+ dependent.
  • 12. Subtypes • HDAC proteins are grouped into four classes based on function and DNA sequence similarity. • Class I, II and IV are considered "classical" HDACs whose activities are inhibited by trichostatin A (TSA) and have a zinc dependent active site, whereas Class III enzymes are a family of NAD+-dependent proteins known as sirtuins and are not affected by TSA. • Homologues to these three groups are found in yeast having the names: reduced potassium dependency 3 (Rpd3), which corresponds to Class I; histone deacetylases 1 (hda1), corresponding to Class II; and silent information regulator 2 (Sir2), corresponding to Class III.
  • 13. • Class IV contains just one isoform (HDAC11), which is not highly homologous with either Rpd3 or hda1 yeast enzymes, and therefore HDAC11 is assigned to its own class. • The Class III enzymes are considered a separate type of enzyme and have a different mechanism of action; these enzymes are NAD+-dependent, whereas HDACs in other classes require Zn2+ as a cofactor.
  • 14.
  • 15.
  • 16. Evolution • HDACs are conserved across evolution, showing orthologs in all eukaryotes and even in Archaea. • All upper eukaryotes, including vertebrates, plants and arthropods, possess at least one HDAC per class, while most vertebrates carry the 11 canonical HDACs, with the exception of bone fish, which lack HDAC2 but appears to have an extra copy of HDAC11, dubbed HDAC12.
  • 17.
  • 18. • Plants carry additional HDACs compared to animals, putatively to carry out the more complex transcriptional regulation required by these sessile organisms. • HDACs appear to be deriving from an ancestral acetyl-binding domain, as HDAC homologs have been found in bacteria in the form of Acetoin utilization proteins (AcuC) proteins
  • 19. Sub cellular distribution • Within the Class I HDACs, HDAC 1, 2, and 3 are found primarily in the nucleus, whereas HDAC8 is found in both the nucleus and the cytoplasm, and is also membrane-associated. • Class II HDACs (HDAC4, 5, 6, 7 9, and 10) are able to shuttle in and out of the nucleus, depending on different signals.
  • 20. • HDAC6 is a cytoplasmic, microtubule-associated enzyme. • HDAC6 deacetylates tubulin, Hsp90, and cortactin, and forms complexes with other partner proteins, and is, therefore, involved in a variety of biological processes.
  • 21. Function Histone modification: • Histone tails are normally positively charged due to amine groups present on their lysine and arginine amino acids. • These positive charges help the histone tails to interact with and bind to the negatively charged phosphate groups on the DNA backbone. • Acetylation, which occurs normally in a cell, neutralizes the positive charges on the histone by changing amines into amides and decreases the ability of the histone to bind to DNA.
  • 22. • This decreased binding allows chromatin expansion, permitting genetic transcription to take place. • Histone deacetylases remove those acetyl groups, increasing the positive charge of histone tails and encouraging high- affinity binding between the histones and DNA backbone. • The increased DNA binding condenses DNA structure, preventing transcription.
  • 23. • Histone deacetylases is involved in a series of pathways within the living system. • According to the Kyoto Encyclopaedia of Genes and Genomes (KEGG), these are: 1. Environmental information processing; signal transduction; notch signalling pathway 2. Cellular processes; cell growth and death; cell cycle 3. Human diseases; cancers; chronic myeloid leukaemia
  • 24. • Histone acetylation plays an important role in the regulation of gene expression. • Hyper acetylated chromatin is transcriptionally active, and hypoacetylated chromatin is silent. • A study on mice found that a specific subset of mouse genes (7%) was deregulated in the absence of HDAC1.
  • 25. • Their study also found a regulatory crosstalk between HDAC1 and HDAC2 and suggest a novel function for HDAC1 as a transcriptional coactivator. • HDAC1 expression was found to be increased in the prefrontal cortex of schizophrenia subjects negatively correlating with the expression of GAD67 mRNA.
  • 26. Non-histone effects • It is a mistake to regard HDACs solely in the context of regulating gene transcription by modifying histones and chromatin structure, although that appears to be the predominant function. The function, activity, and stability of proteins can be controlled by post- translational modifications. • Protein phosphorylation is perhaps the most widely studied and understood modification in which certain amino acid residues are phosphorylated by the action of protein kinases or dephosphorylated by the action of phosphatases.
  • 27. • The acetylation of lysine residues is emerging as an analogous mechanism, in which non-histone proteins are acted on by acetylases and deacetylases. • It is in this context that HDACs are being found to interact with a variety of non-histone proteins—some of these are transcription factors and co-regulators, some are not.
  • 28. Note the following four examples: 1. HDAC6 is associated with aggresomes. – Misfolded protein aggregates are tagged by ubiquitination and removed from the cytoplasm by dynein motors via the microtubule network to an organelle termed the aggresome. – HDAC 6 binds polyubiquitinated misfolded proteins and links to dynein motors, thereby allowing the misfolded protein cargo to be physically transported to chaperones and proteasomes for subsequent destruction. – HDAC6 is important regulator of HSP90 function and its inhibitor proposed to treat metabolic disorders.
  • 29. 2. PTEN is an important phosphatase involved in cell signaling via phosphoinositols and the AKT/PI3 kinase pathway. • PTEN is subject to complex regulatory control via phosphorylation, ubiquitination, oxidation and acetylation. • Acetylation of PTEN by the histone acetyltransferase p300/CBP-associated factor (PCAF) can repress its activity; on the converse, deacetylation of PTEN by SIRT1 deacetylase and, by HDAC1, can stimulate its activity.
  • 30. 3. APE1/Ref-1 (APEX1) is a multifunctional protein possessing both DNA repair activity (on abasic and single-strand break sites) and transcriptional regulatory activity associated with oxidative stress. • APE1/Ref-1 is acetylated by PCAF; on the converse, it is stably associated with and deacetylated by Class I HDACs. • The acetylation state of APE1/Ref-1 does not appear to affect its DNA repair activity, but it does regulate its transcriptional activity such as its ability to bind to the PTH promoter and initiate transcription of the parathyroid hormone gene.
  • 31. 4. NF-κB is a key transcription factor and effector molecule involved in responses to cell stress, consisting of a p50/p65 heterodimer. • The p65 subunit is controlled by acetylation via PCAF and by deacetylation via HDAC3 and HDAC6.
  • 32. Neurodegenerative diseases • Inherited mutations in the gene encoding FUS, an RNA/DNA binding protein, are causally linked to amyotrophic lateral sclerosis (ALS). • FUS has a pivotal role in the DNA damage response involving its direct interaction with histone deacetylase 1 (HDAC1). • ALS mutant FUS proteins are defective in the DNA damage response and in recombinational DNA repair, and also show reduced interaction with HDAC1.
  • 33. • Ataxia-telangiectasia is due to mutation in the Atm gene. Wild- type Atm encodes a protein kinase employed in chromatin remodeling and in epigenetic alterations that are required for repairing DNA double-strand breaks. • Atm mutation causes neurons to accumulate nuclear histone deacetylase 4 (HDAC4) resulting in increased histone deacetylation and altered neuronal gene expression that likely contributes to the neurodegeneration characteristic of ataxia-telangiectasia.
  • 34. HDAC inhibitors • Histone deacetylase inhibitors (HDIs) have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics, for example, valproic acid. • In more recent times, HDIs are being studied as a mitigator or treatment for neurodegenerative diseases. • Also in recent years, there has been an effort to develop HDIs for cancer therapy. • Vorinostat (SAHA) was FDA approved in 2006 for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) that have failed previous treatments.
  • 35. • A second HDI, Istodax (romidepsin), was approved in 2009 for patients with CTCL. The exact mechanisms by which the compounds may work are unclear, but epigenetic pathways are proposed. • In addition, a clinical trial is studying valproic acid effects on the latent pools of HIV in infected persons. • HDIs are currently being investigated as chemosensitizers for cytotoxic chemotherapy or radiation therapy, or in association with DNA methylation inhibitors based on in vitro synergy. • Isoform selective HDIs which can aid in elucidating role of individual HDAC isoforms have been developed.
  • 36. • HDAC inhibitors have effects on non-histone proteins that are related to acetylation. • HDIs can alter the degree of acetylation of these molecules and, therefore, increase or repress their activity. • For the four examples given above (see Function) on HDACs acting on non-histone proteins, in each of those instances the HDAC inhibitor Trichostatin A (TSA) blocks the effect.
  • 37. • HDIs have been shown to alter the activity of many transcription factors, including ACTR, cMyb, E2F1, EKLF, FEN 1, GATA, HNF-4, HSP90, Ku70, NFκB, PCNA, p53, RB, Runx, SF1 Sp3, STAT, TFIIE, TCF, YY1.
  • 38. • The ketone body β-hydroxybutyrate has been shown in mice to increase gene expression of FOXO3a by histone deacetylases inhibition. • Histone deacetylases inhibitors may modulate the latency of some viruses, resulting in reactivation. • This has been shown to occur, for instance, with a latent human herpesvirus-6 infection. • Histone deacetylases inhibitors have shown activity against certain Plasmodium species and stages which may indicate they have potential in malaria treatment. It has been shown that HDIs accumulate acetylated histone H3K9/H3K14, a downstream target of class I HDACs.